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Background: Mycoplasma pneumoniae is an organism that reportedly has a strong relationship 
to asthma. However, asthma severity and location of airway obstruction have not been compared 
between asthmatic patients with and without evidence for remote mycoplasma infection.
Objectives: The aim of this research was to study the relationship between previous 
M. pneumoniae infections in asthmatic patients and presence of any predilection for the 
involvement of central or peripheral airways, the severity of the disease, and asthma control.
Methods: Sixty-two patients with asthma were assessed by a validated asthma control test 
(ACT). All patients underwent spirometry and lung volume studies by body plethysmography. 
The forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), total lung 
capacity (TLC), residual volume (RV), and functional residual capacity (FRC) were mea-
sured. An oropharyngeal swab was obtained for polymerase chain reaction analysis to detect 
the mycoplasma antigen. Moreover, blood samples were obtained to measure the titration of 
antimycoplasma immunoglobulin M (IgM) and IgG antibodies. The asthmatic patients with a 
positive IgG for mycoplasma and negative PCR and negative IgM antibody were considered 
to have remote history of mycoplasma infection. The relationship between the asthma control 
using ACT score and pulmonary function variables were compared in patients with and without 
evidence for remote mycoplasma infection.
Results: The incidence of postnasal drip was higher among the patients with asthma who had 
no evidence for remote mycoplasma infection (61.3% vs 32%, P = 0.035). The median ACT 
score was 16.5 (11–22) and 20 (13.75–24) in patients with and without remote M. pneumoniae 
infection, respectively (P . 0.05). In addition, the medians of the predicted values of the 
pulmonary function test parameters (FEV1, FEV1/FVC, FRC, FRC/TLC, RV/TLC, maximal 
mean expiratory flow 25%–75%, forced expiratory flow [FEF] 50%, and FEF 75%) and actual 
values of 5 Hz and 20 Hz resistance were not different between asthmatic patients with and 
without evidence of mycoplasma infection (P . 0.05).
Conclusions: The present study revealed that the asthma control status and parameters of lung 
function tests did not differ between asthmatic patients with and without evidence of chronic 
M. pneumoniae infection. The latter indicates the similar location of airway obstruction and 
comparable severity of asthma between the two groups.
Keywords: Mycoplasma pneumoniae, asthma, asthma control test, airway, pulmonary 
function test
Introduction
Asthma is a chronic disease characterized by variable airway obstruction. Allergic and 
immunologic factors are deemed to play a cardinal role in the pathogenesis of asthma. 
Recently, imbalance between type 1 and type 2 T-helper lymphocytes (TH) is believed 
DOI: 10.2147/IJGM.S15867International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2
Ansarin et al
to play a major role in development of this disease.1 Factors 
involved in asthma parthogenesis predispose the individual 
to increased differential   overproduction of TH2 cells versus 
TH1 cells.2 Accordingly, a number of infections have been 
considered to be involved in generation of asthma. For 
instance, mycoplasma is an organism reportedly having a 
strong relationship to asthma.3
On the other hand, asthma is a disease of varying pheno-
types among different individuals and in different times in 
the same individual. The severity of asthma is believed to be 
linked to the location of the airway inflammation; asthma is 
more severe and persistent in those with functional and patho-
logical evidence of small peripheral airways involvement 
compared to the central airways involvement.4 The aim of 
the present study was to investigate the relationship between 
previous Mycoplasma pneumoniae infections in asthmatic 
patients and presence of any predilection for the involvement 
of central or peripheral airways, the severity of the disease, 
and asthma control.
Methods
Sixty-two patients with asthma were enrolled after sequential 
random selection after diagnosis of asthma in a pulmonary 
subspecialty clinic by a pulmonologist on the basis of the 
American Thoracic Society guideline for diagnosis of 
asthma. After full history taking, physical examination, 
and assessment of the asthma control by asthma control 
test (ACT),5 all patients underwent spirometry and lung 
volume studies by body plethysmography using Jaeger body-
plethysmograph (Jaeger, Wuerzburg, Germany). The forced 
expiratory volume in 1 second (FEV1), forced vital capacity 
(FVC), total lung capacity (TLC), residual volume (RV), 
and functional residual capacity (FRC) were measured, and 
their ratios and percent predicted values for the individual 
were calculated. Patients with history of smoking, respiratory 
infection within the past 2 months, known cardiac disease, 
congestive heart failure, chronic respiratory disease, or any 
other condition affecting the lung function were excluded 
from study. A throat swab sample was obtained from all 
patients for polymerase chain reaction (PCR) analysis to 
detect the mycoplasma antigen. Moreover, blood samples 
were obtained from the patients to measure the titration of 
antimycoplasma immunoglobulin M (IgM) and IgG anti-
bodies (antimyc-IgM and antimyc-IgG, respectively) using 
enzyme-linked immunosorbent assay (EUROIMMUN Inc, 
Padova, Italy). The asthmatic patients with a positive IgG for 
mycoplasma and negative PCR and negative IgM antibody 
were considered to have remote history of mycoplasma 
infection. The relationship between the asthma control using 
ACT score and pulmonary functional variables including 
the values for FEV1, FVC, RV , TLC, FRC, maximal mean 
expiratory flow (MMEF) 25%–75%, forced expiratory flow 
(FEF) 50% and 75%, and resistance (5 and 20 Hz) and their 
predicted values were analyzed and compared in patients with 
and without evidence for remote mycoplasma infection.
To achieve a power of 80% with a type 1 error rate of 
0.05, the sample size was calculated as 31 patients for each 
group.6 Data are presented as median (interquartile range) 
or percentage. Statistical analysis was performed with SPSS 
for Windows (version 16.0; SPSS Inc., Chicago, IL) by 
using χ2 test, Fisher’s exact test, and Mann–Whitney U test 
wherever appropriate. P , 0.05 was considered statistically 
significant.
Results
Sixty-two asthmatic patients were recruited. Four patients 
were excluded due to positive antimyc-IgM and/or posi-
tive PCR for M. pneumoniae. Data from 58 patients were, 
therefore, analyzed. There were no differences in gender, 
age, and incidence of cough, sputum, wheezing, dyspnea, 
gastroesophageal reflux, and history of atopy between the 
groups (Table 1, P . 0.05). Among different respiratory 
symptoms of asthma, the incidence of postnasal drip (PND) 
was higher among the patients with asthma who had no 
evidence for remote mycoplasma infection (61.3% vs 32%, 
P = 0.035, Table 1). The median ACT score was 16.5 (11–22) 
and 20 (13.75–24) in patients with and without remote M. 
pneumoniae infection, respectively (Mann–Whitney U test, 
P . 0.05, Table 1). In addition, the medians of the predicted 
values of the pulmonary function test parameters (FEV1, 
FEV1/FVC, FRC, FRC/TLC, RV/TLC, MMEF 25%–75%, 
FEF 50%, and FEF 75%) and actual values of 5 Hz and 20 Hz 
resistance were not different between asthmatic patients 
with and without evidence of mycoplasma infection (Mann–
Whitney U test, P . 0.05, Table 2).
Discussion
An association of asthma with mycoplasma infection has 
been believed and investigated by several researchers in 
the past. M. pneumoniae may precede the onset of asthma, 
exacerbate asthma, or play a part in asthma chronicity.7,8 Such 
an association has been demonstrated earlier by isolation 
of M. pneumoniae in oropharyngeal swabs and serologic 
assessments and later by lower airway evaluations.9,10 
Previous studies on patients with chronic asthma revealed 
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individuals.9–11 Nonetheless, Tuuminen et al found no signifi-
cant difference in M. pneumoniae serology between asthmatic 
patients and control group.12 In the present study, we aimed 
to study the relationship between previous M. pneumoniae 
infections in asthmatic patients and presence of any predi-
lection for the proximal or distal airways involvement, the 
severity of the disease, and asthma control.
The present study revealed no significant difference 
in the asthma control status assessed by ACT between 
asthmatic patients with and without evidence of chronic 
mycoplasma infection. In addition, various parameters of 
lung function tests, including tests sensitive to central as 
well as peripheral airway obstruction, did not differ between 
the two groups, indicating similar involvement of central 
and peripheral airways as well as comparable severity of 
asthma. Moreover, among different respiratory symptoms of 
asthma, the incidence of PND was higher among the patients 
with asthma who had no evidence for remote mycoplasma 
infection. To the best of our knowledge, the present study 
is the first investigation to compare the asthma severity and 
location of airway obstruction in asthmatic patients with and 
without evidence for remote mycoplasma infection.
Severity of asthma is measure as the difficulty in control-
ling asthma with treatment after excluding amendable factors.13 
On the other hand, asthma control reflects the patient’s current 
clinical status as well as the future risk of adverse outcomes.13,14 
Following the evidence revealing an association between 
achievement of good asthma control and improved health 
status,15 the level of asthma control rather than the disease 
severity is highlighted more in guideline-based asthma treat-
ment protocols.13 In the present study, we found no difference 
in pulmonary function tests, indicative of the asthma severity, 
in those asthmatics with and without chronic mycoplasma 
infection.
Severe asthma has been attributed to more involvement 
of small (distal) airways rather than proximal airways.4 
Interestingly, Balzar et al reported a relationship between 
chymase-positive mast cells in the distal airways and pulmo-
nary function tests in severe asthma.16 In the present study, 
to determine the location of airway obstruction in asthmatic 
Table 1 Demographic data and symptom frequencies in asthmatic patients with and without remote mycoplasma infection
With remote mycoplasma  
infection (n = 26)
Without remote mycoplasma 
infection (n = 32)
P value
Gender (male/female) 13/13 15/17 1.00
Age (years) 38.5 (29.5–44.25) 38 (29–44.75) 0.83
cough: n (%) 21 (80.8%) 28 (87.5%) 0.71
sputum: n (%) 11 (42.3%) 18 (58.1%) 0.29
Wheezing: n (%) 22 (88%) 22 (73.3%) 0.31
Dyspnea: n (%) 20 (76.9%) 25 (78.1%) 1.00
Gastroesophageal reflux: n (%) 5 (20%) 9 (29%) 0.54
Postnasal drip: n (%) 8 (32%) 19 (61.3%) 0.03*
history of atopy: n (%) 9 (34.6%) 11 (34.4%) 1.00
AcT score 16.50 (11–22) 20 (13.75–24) 0.06
Note: *P , 0.05.
Abbreviation: AcT, asthma control test.
Table 2 Pulmonary function test parameters in asthmatic patients with and without remote mycoplasma infection
With remote mycoplasma 
infection (n = 26)
Without remote mycoplasma 
infection (n = 32)
P value
FeV1 (% predicted) 72.60 (51.92–88.90) 76.65 (53.15–89.27) 0.80
FeV1/FVc 68.60 (62.40–74.05) 70.35 (63.45–80.55) 0.37
Frc (% predicted) 93.15 (82.22–109.50) 93.90 (74.40–105.50) 0.67
Frc/TLc (% predicted) 99.95 (84.40–127.50) 98 (85.4–120) 0.71
rV/TLc (% predicted) 108 (92.02–152) 113 (88.25–139.25) 0.92
MMeF 25%–75% 33.75 (23.07–52.50) 40.55 (21.27–70.02) 0.55
FeF 50% (% predicted) 40.50 (24.47–57.60) 44.60 (23.75–70.67) 0.73
FeF 75% (% predicted) 29.55 (19.20–43.47) 32.55 (20.75–54.35) 0.70
resistance (5 hz) (kpa/L/sec) 0.67 (0.39–0.91) 0.55 (0.39–0.82) 0.66
resistance (20 hz) (kpa/L/sec) 0.35 (0.23–0.51) 0.36 (0.28–0.42) 0.92
Abbreviations: FeV1, forced expiratory volume in 1 second; FVc, forced vital capacity; Frc, functional residual capacity; TLc, total lung capacity; rV, residual volume; 
MMEF, maximal mean expiratory flow; FEF, forced expiratory flow; Hz, Hertz; kpa, kilopascal; L, liter; sec, second.International Journal of General Medicine
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patients with and without remote mycoplasma infection, 
parameters of pulmonary function test (indicative of both 
central and peripheral airway function) were compared. 
However, no superiority of either distal or proximal airways 
involvement was noted between these two groups. Consistent 
with our results, Teig et al found no correlation between posi-
tive PCR for M. pneumoniae and FEV1, the only reported 
parameter in their study, in 26 children with stable asthma.17 
A few investigations on a relation between Chlamydia 
pneumoniae and severity of pulmonary obstruction in 
asthmatic patients exist in the literature. Huittinen and 
colleagues concluded that C. pneumoniae heat-shock protein 
60 IgA antibodies were inversely associated with FEV1.18 
Similarly, Black et al reported an inverse association between 
IgG antibodies to C. pneumoniae and FEV1.19
In conclusion, the asthma control status and parameters 
of lung function tests did not differ between asthmatic 
patients with and without evidence of chronic M. pneumoniae 
infection. The latter indicates the similar location of airway 
obstruction and comparable severity of asthma between the 
two groups. Further investigations with larger sample size 
and focusing on both M. pneumoniae and Chlamydophila 
pneumoniae are needed to strengthen the present findings.
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